FDA Panel Nixes Decitabine for Acute Myeloid Leukemia
February 9, 2012|Oncology Practice
Author and Disclosure Information
FROM A MEETING OF THE FOOD AND DRUG ADMINISTRATION'S ONCOLOGIC DRUGS ADVISORY COMMITTEE
There are currently four FDA-approved first-line drugs for AML. The last drug was idarubicin, approved in 1990.
Another issue highlighted during the discussions was the available treatments for the growing aging population. The medical community is entering somewhat of an uncharted territory and such trials are important, said Dr. William Kevin Kelly, a voting member of ODAC and professor of medical oncology and urology at Thomas Jefferson University, Philadelphia who voted no.
Panelists were cleared of potential conflicts before voting on decitabine.
